The variation in individual responses to exogenous agents is exceptionally wide. It is because of this large diversity of responsiveness that risk factors to environmentally induced diseases have been difficult to pinpoint, particularly at low exposure levels. Opportunities now exist for studies of host factors in cancer or other diseases in which an environmental component can be presumed. Many of the studies have shown an elevated disease proneness for individuals carrying the potential at-risk alleles of metabolic genes, but a number of controversial results have also been reported. This article is an overview of the data published to date on metabolic genotypes related to individual susceptibility to cancer. -Environ Health Perspect 1 07(Suppl 1): 37-47 (1999). http.//ehpnetl.niehs.nih.gov/docs/1999/Suppl-1/37-47hirvonen/abstract.html
cell-cycle control genes that occur through gene mutations, gene rearrangements, and gene/chromosome deletion (3, 4) . The overall process can occupy a major portion of the lifespan of an individual.
The paradigm for mechanism of action of chemical carcinogens has been well established in model cell culture and animal systems, and studies in humans appear to support the possibility that most cancers are initiated by chemical/dietary exposures and proceed through various stages of preneoplastic lesions consisting of partially transformed cells to full metastatic cancers (1) . In rodent models, the progression stage can be enhanced by treatment with tumor promoters, which themselves do not necessarily exhibit the properties of carcinogens (5) . These chemicals are thought to mediate cell proliferations that fix the mutation in the genome. Another class of chemicals called nongenotoxic carcinogens has been described in rodent model systems (6) (7) (8) . These agents are not metabolically activated to genotoxic derivatives but presumably alter cell-cycle control. Many nongenotoxic carcinogens are also tumor promoters. However, their mechanisms of action are not presently known.
It is widely held that humans differ in their susceptibilities to cancer. Certain individuals may be more susceptible, whereas others are more resistant to cancer. This may be due to a number of factors including health, nutritional status, and gender.
From what is known about the mechanism of action of carcinogens, it is thought that genetic background could play a significant role. The obvious candidate genes are those encoding the xenobiotic-metabolizing enzymes (XMEs) that activate or inactivate carcinogens (9, 10) . Variable levels of expression of these enzymes could result in increased or decreased carcinogen activation. In fact, it is well established that genetic differences occur in expression of the XMEs. Scientists have been aware of genetically based differences in sensitivity to therapeutically used drugs for more than 30 years. This knowledge led to a field known as pharmacogenetics (11) . Historically, this term was used to describe genetic differences in drug metabolism, but the field later expanded into the area of cancer susceptibility (12) .
XME Polymorphisms and Cancer Susceptibility Cyohomes P450s
The cytochrome P450 (CYP)-dependent monooxygenases represent the first line of defense against toxic lipophilic chemicals because they catalyze reactions involving incorporation of an atom of molecular oxygen into the substrate (13) . The resulting increase in hydrophilicity facilitates further metabolic processing and excretion. Unfortunately, certain chemicals are activated to their ultimate carcinogenic form rather than being detoxified. Most carcinogen activation occurs through generation of epoxides or N-hydroxy intermediates that are further metabolized by transferases.
The main CYPs in humans that metabolize carcinogens are CYPlAl, CYP1A2, CYPIBI, CYP2A6, CYP2E1, CYP3A4, and CYP3A5 (14) . These enzymes have specificities for various classes of carcinogens and genetic polymorphism has been identified for most of them (13) (14) (15) (16) . CYPs are most extensively expressed in the liver although their levels of expression vary depending on the P450 form (17) . These (75) (76) (77) (78) (79) . Although these polymorphisms do not appear to alter the primary sequence of the enzyme, an effect on gene transcription has been suggested (80) . However, no correlation has been found between the variant alleles of CYP2E1 and its expression in vitro or in vivo (81) (82) (83) (84) (85) (86) (87) . In a Japanese study, individuals homozygous for the variant DraI alleles of CYP2E1 were reported to have decreased lung cancer risk, especially individuals with high cumulative smoking doses (88, 89) . This genotype was found less frequently in the Finnish than in the Japanese population (90) . Moreover, no differences were observed in the frequency of this genotype between lung cancer patients and controls, a finding that agreed with Swedish observations (91) . Also, the variant RsaI allele was extremely rare among Scandinavians (90, 91) . However, a Swedish study suggested that homozygosity for the RsaI allele poses an increased risk of lung cancer (91) , whereas a Taiwanese study suggested that this allele was associated with increased risk of nasopharyngeal carcinoma (92 The mEH enzyme is expressed in all tissues thus far examined, with highest levels in the liver, kidney, and testis, and 10-to 100-fold lower levels in the lung and lymphocytes (95) (96) (97) . Within cells, mEH is localized mainly to the endoplasmic reticulum where it can transiently associate with the CYP mixed-function oxygenase system (98) . Endogenous substrates for mEH have not been readily identified. However, the high degree of mEH structural conservation between several mammalian species and apparent ubiquitous tissue expression imply that mEH has an important role in cellular metabolism (96) .
Interindividual differences in mEH activity ranging from several-to 40-fold have been reported in various human tissue types (96) . The molecular basis for variation in mEH activity has not yet been characterized completely. Genetic polymorphisms have, however, been identified within exons 3 and 4 of the mEH gene (EPIX) (99, 100) , which results in His113 Tyr and Arg139His amino acid substitutions, respectively. In vitro expression analyses indicated that the corresponding mEH activities decrease approximately 40% (Tyr113) or increase by at least 25% (His139). The activity level observed in the presence of both variations approximates that observed for the wild-type genotype (100) . Recently a genetic variation in the 5' flanking sequence of EPHX was observed. This may be an additional contributing factor to the range of functional mEH expression existing in human populations (101) .
Data from the few studies addressing a possible association between EPHX polymorphisms and cancer support a dual role for the mEH in the carcinogenic process. It has been suggested that the EPHXHis113 variant allele increases the risk of aflatoxin-associated hepatocarcinoma (102) but decreases the risk of ovarian cancer (103) . With regard to lung cancer, no significant association was found to the EPHXgenotypes (104).
Glutathione S-Transferases
Among the detoxification systems, the glutathione S-transferases (GSTs) play a critical role in providing protection against electrophiles and products of oxidative stress (105) . GSTs are a superfamily of enzymes that have broad and overlapping substrate specificities. Four families of cytosolic soluble GSTs have so far been identified in humans and are referred to as alpha, mu, pi, and theta (105) . The known substrates for GSTs in cigarette smoke are those derived from in bioactivation from PAHs, namely, PAH diolepoxides. The most studied carcinogenic PAH diolepoxide, BaPDE, is a good substrate for many GST isoforms like GSTM2, GSTM3, and especially for GSTM1 and GSTP1 (105, 106) . In general, class mu enzymes show highest activities with most epoxides.
To date, genetic polymorphism has been found in four of the GST genes. One of these is GSTM1, which is expressed in only about half of Caucasians because of a homozygous deletion (null genotype) of the gene in the other half (107) . In addition to the null genotype, two functional alleles denoted as GSTMI *A and GSTMI *B have been described. These alleles differ by a base substitution (C534G) in the latter, which has not been shown to affect GSTM1 activity.
In several recent studies an increased risk of cancer has been observed among GSTMI null smokers, but several conflicting reports also exist (50, (108) (109) (110) . In light of the compiled data it has been estimated that 17% of both lung cancers (110) (112, 115) .
People with low expression of GSTM3 were previously observed to be at increased risk of developing adenocarcinoma of the lung (114 (119, 120) . Individuals homozygous for the GSTP1 *B alleles have been suggested to detoxify the ultimate carcinogen of BaP, i.e., (+)-anti-BaPDE, more efficiently than heterozygotes or wild-type homozygotes (121) . Hence, they could also be less susceptible to the carcinogenic effects of BaP.
In a recent study, a 3-fold increased risk of bladder and testicular cancer was observed for individuals homozygous for the GSTP1 low-activity alleles (GSTPI *B and GSTP1 C alleles not differentiated) compared to controls (122) . A similar association was also reported for cancers of the larynx (123) and lung (124), followed by both supporting and contrasting findings (73, 118, 125, 126) .
A deletion polymorphism similar to that observed for GSTM1 has also been discovered for the GSTTI gene (127) . The prevalence of GSTTI null individuals shows a wide variation among ethnically different populations; in Caucasians the prevalence is 10 to 20% (108) . GSTTI participates in detoxification of potentially carcinogenic monohalomethanes (128) and reactive epoxide metabolites of butadiene (129, 130) , both of which are constituents of tobacco smoke. The GSTT1 null genotype has been associated with increased risk of lung (131) and larynx cancers (132) , but like the GSTMI null genotype, controversial reports also exist (125, (133) (134) (135) (137, 138) . The NAT2 (139) , which was until recently thought to be the only polymorphic N-acetyltransferase (NAT), is responsible for the well-known inherited interindividual variation in the ability to acetylate substrates such as the arylamine drugs procainamide and sulfamethazine, the arylamine carcinogen benzidine, and some hydrazine drugs such as isoniazid and hydralazine (137, 138) . Recently another human N-acetyltransferase, NATI (138) , which is widely expressed in tissues (140) and cultured cells (141) , has also been found to be polymorphic (142) .
These findings may be of great clinical and toxicologic importance because certain chemicals may be N-acetylated to a significant degree by both NATI and NAT2.
These include the carcinogenic aromatic amines 2-aminofluorene, benzidine, 4-aminophenyl, 4,4-dichloroaniline, and 2-naphthylamine (143) (144) (145) (146) (147) (148) , and the cancer chemotherapeutic agent dinaline (4-amino-N-[2'-aminophenyl] benzamide) (149) . They are encoded at two distinct loci on chromosome 8p21.3-23.1 along with NATP, a pseudogene that does not encode a functional protein (150) . The new nomenclature of NATi and NAT2 alleles used henceforth in this review is based on the consolidated classification system ofVatsis et al. (151) .
Seven NATI alleles in human populations have been reported in the literature (150) . The NA Tl *4allele is denoted as the wild type. A prominent change in one of the variants (NA TI *10), which has an alteration of the consensus polyadenylation signal (142) , was recently reported to be associated with both higher NATI activity in bladder and colon tissue and DNA adduct levels in the colon tissues (152, 153) . Given that NATI has been reported to be primarily responsible for the NAT activity in the human uroepithelium (154) (161, 169) . In urinary bladder carcinogenesis, N-acetylation of arylamines is a competing pathway for N-oxidation. The unconjugated N-hydroxy metabolites can enter the circulation, undergo renal filtration, and be transported to the urinary bladder (170) . A number of previous phenotyping studies provided evidence that the NAT2 slow acetylator phenotype is a significant risk factor for the occurrence of bladder cancer, particularly for individuals occupationally exposed to arylamines. Subsequent genotyping studies supported the important role of NAT2 slow acetylation status as a risk factor for arylamineinduced bladder cancer (168, 171, 172) . There is, however, also the possibility that slow acetylators survive longer than rapid acetylators in patients with bladder cancer (173) . Recent data suggest that a prominent variant allele of NA Ti (NA Ti *10) associated with increased enzyme activity is also a risk factor for smoking-related bladder cancer (174) .
Another area of research is based on the hypothesis that fast acetylators are at increased risk for cancers at sites other than the bladder because of the activation of procarcinogens such as heterocyclic amines. Exposure to heterocyclic amines is fairly common; these potent mutagens and rodent carcinogens are formed when meat and fish are cooked at household temperatures. The heterocyclic amines are poor substrates for N-acetylation in human liver, but they readily undergo hepatic N-oxidation and subsequent N-glucuronidation, which results in conjugated N-hydroxy metabolites that can be transported to the colonic lumen (175) . In colonic mucosa, the N-hydroxy derivatives are good substrates for O-acetylation, which results in reactive N-acetoxyarylamines capable of forming covalent DNA adducts (170) . The association between the NATI fast acetylator trait and colorectal tumors could be due to enhanced O-acetylation of aromatic amines in cigarette smoke or to heterocyclic amines in cooked meat because both smoking and high intake of red meat have previously been associated with colorectal cancer (176, 177) . The role of NATI activity is less clear if heterocyclic amines are the aromatic amine compounds of primary relevance to human colorectal cancer. Some data indicate that among the acetyltransferases, NAT2 is more important than NATI for bioactivation of heterocyclic amines in vitro (178) (179) (180) (181) .
Several previous phenotyping studies (168) suggest that rapid acetylators are at higher risk to develop cancer of the colon. Several recent genotyping studies have reached a similar conclusion (168) . Moreover, preliminary data suggest that the NA Ti *10 allele is also a risk factor in smoking-related colon cancer (158, 182) .
The N-acetylation phenotype also has been widely studied in relation to susceptibility to breast and lung cancer. Several case-control studies compared the prevalence of the slow acetylator phenotype in breast cancer patients with the prevalence found in controls; their outcomes were mixed (168) . Similarly, a recent genotyping study indicated an increased risk of breast cancer for slow NAT2 acetylators who smoked 20 or more cigarettes per day (183) . However, two subsequent studies provided little evidence of an association between the NA T2 genotypes and breast cancer (184, 185) .
Other studies have evaluated the utility of acetylation as an indicator of risk for pulmonary malignancies and liver cancer.
A set of four phenotyping studies yielded inconclusive results about the potential association between the NAT2 acetylator status and lung cancer risk [for a review, see Hirvonen (168) . Subsequent genotyping studies also did not give any conclusive evidence (186) (187) (188) . However, the potential role of NATgenotypes as modifiers of individual responses to environmental agents is supported in three recent studies that found that the NA T2 slow acetylator genotype posed an increased risk of mesothelioma (189) and hepatocellular carcinoma (190) , whereas the NATI highactivity allele increased risk of smokingrelated lung cancer (160) .
It is possible that N-acetylation is an important detoxification step in environmental exposures. The combination of the NA TI and NA T2 susceptible genotypes possibly is a particularly unfavorable genotype composition in arylamine exposures. In support of this possibility, Bell et al. (158) recently observed that the association between increased risk of colorectal cancer and the fast NA TJ acetylator allele (NA TI *10) was most apparent among fast NAT2 acetylators. Moreover, this genotype combination together with high red meat intake caused a remarkably increased risk of colon cancer (182) . Further addressing the potential importance of individual acetylation capacity, Badawi et al. (153) found that the carcinogenic DNA adduct levels in the mucosa of the urinary bladder were highest in arylamine-exposed individuals who had inherited both the slow NAT2 acetylator genotype and the rapid NATi acetylation-associated (NA TI *10) allele. NAD(P)H:Q!uinone Oxidoreductase NAD(P)H:quinone oxidoreductase reduces quinones to dihydroquinones, a reaction considered to be critical in the detoxification of these highly reactive metabolites (191) . It is an important enzyme in both activation and detoxification pathways known to protect against the carcinogenicity and mutagenicity of quinone compounds and their metabolites and to activate procarcinogenic compounds (192) . A polymorphic allele of the human NQOi gene, with an amino acid change causing low catalytic activity (193) (194) (195) , recently was associated with increased susceptibility to malignancies such as colon and lung cancer (195) (196) (197) (198) (199) and local release of MPO (200, 201) . MPO activates carcinogens such as BaP and aromatic amines in tobacco smoke (170, 202) . An allelic variant with a G to A base substitution in the promoter region of the MPO gene recently has been shown to result in reduced gene transcription. Homozygotes for the variant allele recently have been suggested to be less susceptible to lung cancer (203) .
Sulfotransferases, which exist as a superfamily, can participate in the metabolic activation of arylamine and heterocyclic amine carcinogens (204) .
The uridine diphosphate (UDP)-glycosyltransferases (UGTs) conjugate active metabolites of carcinogens and multiple forms are expressed in liver and extrahepatic tissues (205) (206) (207) . UGTs can also participate in the metabolism of arylamines and heterocyclic amines. Although genetic defects in a form of UGT that conjugates bilirubin have been described, genetic differences in their expression have not been demonstrated (208) .
The flavin-containing monooxygenases (FMOs) are a superfamily of xenobioticmetabolizing enzymes that oxidize numerous nucleophilic compounds (209, 210) . These enzymes primarily carry out the inactivation of drugs and do not activate the common classes of carcinogens (209) .
A low-frequency polymorphism was found in FMO Al. This gives rise to a condition called trimethylaminurea or Fish Odor Syndrome, which is due to an individual's inability to carry out the N-oxidation of tertiary aliphatic amines found in foodstuffs (210) .
The serum paraoxonase/acetylesterase catalyzes the hydrolysis of organophosphate pesticides such as paraoxon, carbamates, and carboxylic acid esters. It also hydrolyzes mustard gas and Sarin. A genetic polymorphism resulting in a highactivity and a low-activity allele has also been found in this enzyme (211, 212) .
Future Directions
It is anticipated that rapid advances will be made in methodology to determine potential metabolic at-risk genotypes. These 
